NCT01634269已完成不适用
Medtronic MDT-2111 CoreValve Japan 23mm Study
Medtronic Cardiovascular4 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2012年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA).
研究概览
简要总结
The primary objective of the present trial is to demonstrate the safety and effectiveness of the MDT-2111 in the treatment of symptomatic severe aortic stenosis in subjects with small aortic annuli and deemed difficult for surgical operation.
详细描述
The purpose of this trial is to evaluate the effectiveness and safety of the MDT-2111 TAV system in subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention. The primary endpoint is a composite of functional effectiveness as measured by improvement of at least 1 New York Heart Association (NYHA) class from baseline to 6 months and anatomical effectiveness as measured by Effective Orifice Area (EOA) ≥1.0 cm² at 6 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject must have co-morbidities such that one cardiologist and one cardiac surgeon agree that medical factors preclude operation, based on a conclusion that the probability of death or serious morbidity exceeds the probability of meaningful improvement.
- •Subject has senile degenerative aortic valve stenosis with:
- •mean gradient > 40 mmHg or jet velocity greater than 4.0 m/s by either resting or dobutamine stress echocardiogram, or simultaneous pressure recordings at cardiac catheterization (either resting or dobutamine stress), AND an initial aortic valve area of ≤ 0.8 cm² (or aortic valve area index ≤ 0.5 cm²/m²) by resting echocardiogram.
- •Subject is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA Functional Class Class III or greater. If screening committee agrees the eligibility of a patient with class II , based on medical factors, he/she can be enrolled.
- •Patient has been informed of the nature of the trial and has signed an Informed Consent Form.
- •Patient agrees to comply with specified follow-up evaluations and to return to the same investigational site where the procedure was performed.
排除标准
- •Evidence of an acute myocardial infarction ≤ 30 days prior to the intended treatment.
- •Any percutaneous coronary or peripheral interventional procedure performed within 30 days prior to the procedure.
- •Blood dyscrasias as defined:
- •Leukopenia (WBC count < 1,000 cells/mm³)
- •Thrombocytopenia (platelet count <50,000 cells/mm³)
- •History of bleeding diathesis or coagulopathy
- •Hypercoagulable states
- •Untreated clinically significant coronary artery disease requiring revascularization.
- •Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
- •Need for emergency surgery for any reason.
- •Severe ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% as measured by resting echocardiogram.
- •Recent (within 6 months) cerebrovascular accident (CVA) or transient ischemic attack(TIA).
- •End stage renal disease requiring chronic dialysis.
- •GI bleeding within the past 3 months.
- •A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:
- •Ticlopidine
- •Contrast media
- •Nitinol (titanium and nickel alloy)
- •Ongoing sepsis, including active endocarditis.
- •Subject refuses a blood transfusion.
- •Life expectancy < 12 months due to associated non-cardiac co-morbid conditions.
- •Other medical, social, or psychological conditions that in the opinion of an Investigator precludes the subject from appropriate consent.
- •Severe dementia (resulting in either inability to provide informed consent for the trial/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
- •Currently participating in an investigational drug or another device trial. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- •Symptomatic carotid or vertebral artery disease.
- •Native aortic annulus size < 18 mm or > 20 mm per the screening diagnostic imaging.
- •Pre-existing prosthetic heart valve in any position.
- •Mixed aortic valve disease (aortic stenosis and aortic regurgitation with predominant aortic regurgitation).
- •Mitral regurgitation (moderate to severe) or severe tricuspid regurgitation.
- •Moderate to severe mitral stenosis.
- •Hypertrophic obstructive cardiomyopathy.
- •Echocardiographic evidence of intracardiac mass, thrombus or vegetation.
- •Severe basal septal hypertrophy with an outflow gradient.
- •Ascending aorta diameter > 34 mm
- •Congenital bicuspid or unicuspid valve verified by echocardiography.
- •For patients with native coronary artery dependent circulation:
- •Sinus of valsalva width < 25 mm OR
- •Height of the left or right coronary sinus of valsalva (to the tubular aorta) < 15mm.
- •Femoral or iliac artery of the first choice corresponding to any one of the following:
- •Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70°.
- •Vessel diameter of femoral or iliac artery is less than 6 mm.
- •Aorta has severe calcification, excess tortuosity or severe atherosclerosis.
- •Transarterial access not able to accommodate an 18Fr sheath.
- •Subclavian artery of the second choice corresponding to any one of the following:
- •Angle at aortic root (the angle between aortic valve annulus plane and horizontal plane/vertebra) exceeds 70° (in the case of left subclavian artery) and 30° (in the case of right subclavian artery).
- •Vessel diameter of subclavian artery is less than 6 mm.
- •Transarterial access not able to accommodate an 18Fr sheath.
- •Direct Aortic Artery as third line choice of access. Patients are excluded from Direct Aortic access if:
- •Access site is less than 6 cm from the aortic valve basal plane
- •Access site has calcification or porcelain aorta
- 另有 1 项未显示
研究组 & 干预措施
MDT-2111 TAVI 23 mm
Experimental
Subjects with small annuli and symptomatic severe AS deemed difficult for surgical intervention.
干预措施: MDT-2111 TAVI 23 mm (Device)
结局指标
主要结局
Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA).
时间窗: baseline and 6 months
The primary endpoint is a composite of functional effectiveness as measured by improvement of at least 1 NYHA class from baseline to 6 months and anatomical effectiveness as measured by Effective Orifice Area (EOA) ≥1.0 cm² at 6 months.
次要结局
- Repeat Hospitalization(0 day to 24 months)
- Major Adverse Cardiovascular and Cerebrovascular Event (MACCE)(0 day to 24 months)
- Echocardiographic Assessment of Prosthetic Valve Performance - Total Aortic Regurgitation (Transvalvular & Paravalvular) (Total AR)(24 months)
- Valve-related Deaths(0 day to 24 months)
- Device Success as Defined in the Description.(after procedure or discharge)
- Echocardiographic Assessment of Prosthetic Valve Performance - Left Ventricular Ejection Fraction (LVEF)(24 months)
- Echocardiographic Assessment of Prosthetic Valve Performance - Mean Gradient(24 months)
- New York Heart Classification (NYHA) Over Time(24 months)
- Procedural Success, Defined as Device Success and Absence of In-hospital MACCE(from admission for procedure to discharge)
- Echocardiographic Assessment of Prosthetic Valve Performance - Effective Orifice Area (EOA)(24 months)
- Quality of Life Assessment Using SF-36 Questionnaire - Physical Component Summary (Paired Change From Baseline)(Baseline to 24 months)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
不适用
Clinical Evaluation of MDT-2111 in Subjects With Symptomatic Severe Aortic StenosisAortic Valve StenosisNCT01437098Medtronic Cardiovascular55
已完成
不适用
RESOLUTE Japan SVS: The Clinical Evaluation of the MDT-4107 DES in the Treatment of De Novo Lesions in Small Diameter Native Coronary ArteriesArterial Occlusive DiseasesCardiovascular DiseasesCoronary Artery DiseaseMyocardial IschemiaNCT01150500Medtronic Vascular65
已完成
不适用
MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal ArteryFemoral Artery StenosisPopliteal Artery StenosisFemoral Artery OcclusionPopliteal Artery OcclusionNCT01947478Medtronic Endovascular100
已完成
不适用
PERIGON Japan TrialAortic StenosisNCT02686814Medtronic Cardiac Surgery25
已完成
不适用
RESOLUTE Japan - The Clinical Evaluation of the MDT-4107 Drug-Eluting Coronary StentArterial Occlusive DiseasesCardiovascular DiseasesCoronary Artery DiseaseMyocardial IschemiaNCT00927940Medtronic Vascular100